Concurrent use of another NSAID (including aspirin) with Arcoxia increases the risk of gastrointestinal bleeding and cardiovascular events. It is generally advised to avoid combining NSAIDs unless a specialist explicitly recommends it.
Take the missed tablet as soon as you remember, unless it is close to the time of your next scheduled dose. Do not double the dose; simply continue with your regular dosing schedule.
Both strengths have the same safety profile, but higher doses are associated with a greater risk of cardiovascular and gastrointestinal side effects. The lowest effective dose should be used, and dose escalation should only occur under medical supervision.
Arcoxia is contraindicated during pregnancy, especially in the third trimester, due to potential risks to the fetus and complications during delivery. Alternative analgesics should be discussed with a healthcare professional.
Both drugs relieve gout pain, but Arcoxia, as a selective COX-2 inhibitor, may cause fewer stomach problems than ibuprofen. However, cardiovascular risk considerations differ, and the choice should be individualized by a clinician.
Etoricoxib can cause fluid retention and may raise blood pressure, especially at higher doses. Regular blood pressure monitoring is recommended, and dose adjustments may be needed for hypertensive patients.
Long-term use is possible but requires periodic assessment of cardiovascular, renal, and hepatic health. The lowest effective dose should be maintained, and routine monitoring is essential.
No specific foods need to be avoided, but limiting alcohol consumption can reduce gastrointestinal irritation. Taking the pill with a meal can also help minimize stomach upset.
Yes, Arcoxia is approved for short-term management of dental pain. It should be used at the lowest effective dose and for the shortest duration necessary.
Symptoms may include rash, itching, swelling of the face or throat, severe dizziness, or difficulty breathing. Seek emergency medical care immediately if any of these occur.
Arcoxia is a prescription medication that contains etoricoxib as its active ingredient. Etoricoxib belongs to the class of cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) and is used for the relief of pain and inflammation. In the United Kingdom, Arcoxia is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is supplied as a pill in strengths of 60 mg, 90 mg, and 120 mg.
Etoricoxib selectively inhibits the COX-2 enzyme, which is responsible for producing prostaglandins that promote inflammation, pain, and fever. By blocking COX-2 while sparing the COX-1 enzyme (which protects the stomach lining and supports platelet function), etoricoxib reduces inflammatory symptoms with a lower risk of gastrointestinal irritation compared with non-selective NSAIDs. The drug is well absorbed after oral administration, reaches peak plasma concentrations within 1-2 hours, and has a half-life of approximately 22 hours, allowing once-daily dosing for many indications.
Arcoxia is approved by the MHRA for the following adult indications:
These uses reflect the drug’s ability to control inflammation and associated pain in musculoskeletal conditions.
This article provides educational information about Arcoxia (etoricoxib) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.